Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

IDO1 induces immune suppression in T cells through l-tryptophan (Trp) depletion and kynurenine (Kyn) accumulation in the local tumor microenvironment, suppressing effector T cells and hyperactivating regulatory T cells (Treg). Navoximod is an investigational small-molecule inhibitor of IDO1. This ph...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research Jg. 25; H. 11; S. 3220
Hauptverfasser:	Jung, Kyung Hae, LoRusso, Patricia, Burris, Howard, Gordon, Michael, Bang, Yung-Jue, Hellmann, Matthew D, Cervantes, Andrés, Ochoa de Olza, Maria, Marabelle, Aurelien, Hodi, F Stephen, Ahn, Myung-Ju, Emens, Leisha A, Barlesi, Fabrice, Hamid, Omid, Calvo, Emiliano, McDermott, David, Soliman, Hatem, Rhee, Ina, Lin, Ray, Pourmohamad, Tony, Suchomel, Julia, Tsuhako, Amy, Morrissey, Kari, Mahrus, Sami, Morley, Roland, Pirzkall, Andrea, Davis, S Lindsey
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 01.06.2019
Schlagworte:	Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - pharmacokinetics Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use B7-H1 Antigen - antagonists & inhibitors Biomarkers, Tumor Humans Imidazoles - administration & dosage Imidazoles - pharmacokinetics Indoleamine-Pyrrole 2,3,-Dioxygenase - antagonists & inhibitors Indoles - administration & dosage Indoles - pharmacokinetics Magnetic Resonance Imaging Middle Aged Neoplasm Metastasis Neoplasm Staging Neoplasms - diagnosis Neoplasms - drug therapy Neoplasms - etiology Neoplasms - metabolism Tomography, X-Ray Computed Treatment Outcome
ISSN:	1557-3265, 1557-3265
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!